Can a patient with hepatitis C who was treated with Harvoni (sofosbuvir/ledipasvir) six years ago and now has a reinfection be treated with Mavyret (glecaprevir + pibrentasvir)?

Can Mavyret Be Used for HCV Reinfection After Prior Harvoni Treatment?

Yes, a patient with hepatitis C reinfection after Harvoni treatment 6 years ago can be treated with Mavyret (glecaprevir/pibrentasvir). This represents a new infection rather than treatment failure, and should be approached as initial treatment of the current infection.

Key Distinction: Reinfection vs. Relapse

The critical factor here is that this is a reinfection occurring 6 years after successful treatment, not a treatment failure or relapse. According to AASLD-IDSA guidelines, "recurrent HCV viremia after attainment of SVR represents either reinfection or a relapse" 1. The 6-year interval strongly suggests reinfection rather than relapse of the original strain.

With reinfection, treatment approaches are identical to those for initial treatment 1. This means you do not need to treat this as a "treatment-experienced" patient in the context of DAA failure.

Treatment Recommendation

For Patients Without Cirrhosis or With Compensated Cirrhosis:

• Mavyret (glecaprevir/pibrentasvir) for 8 weeks for all genotypes (1-6) 2
• This applies regardless of the HCV genotype of the reinfection
• No genotyping is required if using this simplified approach 2

Treatment Duration by Clinical Scenario:

• No cirrhosis: 8 weeks of Mavyret 3
• Compensated cirrhosis (Child-Pugh A): 8 weeks of Mavyret 3

Important Caveats

When This Approach Does NOT Apply:

You would only need to consider this patient as "treatment-experienced" requiring longer therapy (12-16 weeks) if:

1. The patient had documented treatment failure (not SVR) with Harvoni originally
2. This is a relapse (same viral strain re-emerging), not reinfection
3. The patient has decompensated cirrhosis (Child-Pugh B or C) - in which case Mavyret is contraindicated 3

Pre-Treatment Requirements:

Before initiating Mavyret, you must:

• Test for hepatitis B (HBsAg and anti-HBc) - HBV reactivation is a boxed warning 3
• Assess for cirrhosis using non-invasive methods (FIB-4, APRI, or elastography) 2
• Check for drug-drug interactions - Mavyret is contraindicated with atazanavir and rifampin 3
• Confirm HCV viremia with HCV RNA or core antigen testing 2

Special Populations:

The FDA label confirms Mavyret is approved for patients who are:

• Treatment-naive (which reinfection represents) 3
• Have any degree of renal impairment, including hemodialysis 3
• HIV-coinfected 3

Clinical Evidence Supporting This Approach

Real-world data demonstrates excellent efficacy of Mavyret in various populations:

• SVR12 rates of 99-100% in treatment-naive patients across all genotypes 2, 4, 5
• Effective in reinfection scenarios: A study specifically showed 98.1% SVR12 in patients with acute HCV who had prior HCV infection 6
• Well-tolerated with minimal adverse events (primarily fatigue and pruritus) 7, 5

Monitoring and Follow-Up

• On-treatment monitoring: Not required unless adherence concerns or treatment-related side effects develop 1
• Post-treatment: Check HCV RNA ≥12 weeks after completing treatment to confirm SVR 1
• Ongoing risk: If the patient has continued risk factors for HCV exposure (injection drug use, high-risk sexual activity), recommend annual HCV RNA testing 1, 6

Bottom Line

Treat this reinfection as you would any treatment-naive patient: 8 weeks of Mavyret with food, taken as 3 tablets once daily. The prior Harvoni treatment 6 years ago does not affect this recommendation because this is a new infection, not a treatment failure requiring salvage therapy.